Sucampo Pharmaceuticals to Host Third Quarter 2007 Financial Results Conference Call on November 13, 2007

Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP) an emerging pharmaceutical company developing prostone-based therapies for age-related and other diseases, will release its third quarter 2007 financial results before the opening of the market on Tuesday, November 13 and host a conference call for investors that day at 10:00 a.m. ET.

Ryuji Ueno, M.D., Ph.D., Ph.D., the founder, chairman and chief executive officer of Sucampo Pharmaceuticals, will lead the call, during which management will discuss the Company’s financial results, business outlook and growth strategy.

The call will be accessible on the Company’s website, www.sucampo.com, or by dialing (888) 677-8780 (domestic) or (913) 981-5543 (international). If you are unable to listen to the live call, the webcast will be archived on the Company’s website.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an emerging pharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals’ first product, AMITIZA® (lubiprostone), received marketing approval from the FDA in January 2006. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.